Kronos Bio Inc logo


Kronos Bio Inc


Earnings Summary

Net Profits


Net Profits:

Kronos Bio Inc’s net profit fell -13.24% since last year same period to $-32.9Mn in the Q2 2022. On a quarterly growth basis, Kronos Bio Inc has generated 9.27% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kronos Bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Kronos Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a -4.55% fall from last quarter’s estimates.

EPS Estimate Current Year:

Kronos Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.69.

Key Ratios

Key ratios of the Kronos Bio Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kronos Bio Inc’s return on assets (ROA) stands at -0.26.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kronos Bio Inc’s return on equity (ROE) stands at -0.46.

Dividend Per Share (DPS):

Kronos Bio Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio Inc
Health Technology